|
Zangani Investor Community Week in Review: May 16, 2008 |
||
WEBCASTS ![]() Interview with John B. Nano, Chairman, President and CEO of Competitive Technologies, Inc. Zangani Investor Community(TM) interviews John B. Nano, Chairman, President and Chief Executive Officer of Competitive Technologies, Inc. Mr. Nano discusses CTT's first successful transaction of it's new technology, developed in Italy for pain management, and how the company is working to commercialize additional business opportunities in Italy. (READ MORE)
NEWS
Competitive Technologies' CEO Details Pain Therapy Technology in Interview Competitive Technologies, Inc. (AMEX:CTT - News) announced that John B. Nano, CTT's Chairman, President and CEO in an interview today discussed CTT's exclusive worldwide distribution rights to its pain therapy device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The CTT device has Medical Device CE certification from the European Union allowing European sales and CTT has applied for FDA 510(k) medical device authorization for U.S. sales of the device. The patented device uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. (READ MORE)
BLOGS ![]() Declare War on Oil Before It's Too Late Imagine if President Bush, after 9/11, simply declared war on oil and put the whole nation behind ending our crippling dependence on it. Imagine if we had spent the money we allocated to the war in Iraq toward eliminating the oil addiction. The tab for the Iraq war hovers around the $1 trillion mark and grows at a clip of at least $12 billion a month. The Congressional Budget Office projects that the cost through 2017, including hidden costs such as veterans' benefits, could total $2.4 trillion. (READ MORE)
VIDEOS While the excitement continues to swirl around the recent breakthrough of converting skin cells to stem cells, other researchers are quietly pursuing a new type of stem cell discovered in menstrual blood. These menstrual stem cells could offer several advantages. They come from a source that's easy to obtain from women, they could be used to treat patients without the fear of tissue rejection, and they avoid the ethical questions associated with embryonic stem cells. (READ MORE)
UPCOMING EVENTS
Pharma Finance 2008
The Zangani Investor CommunityTM is proud to present Pharma Finance 2008 scheduled for May 22-23, 2008 (Thursday and Friday), in Roma, Italy. Pharma Finance 2008 features Investment Funds, Multinational/European Pharma Companies, as well as multiple Research Centers participating in the Conference, to offer a three-dimensional view of the European markets and further enhance our presenting companies' attendance. Additionally, specific round tables will be conducted in order to explore medical, scientific, and business opportunities for all the participants of the meeting. Pharma Finance 2008 is scheduled to be our largest event to date, designed to support in-depth partnership and collaboration development with 24 presenting groups. (READ MORE) |
||
|
© 2008 Zangani Investor Community, Unsubscribe from this newsletter. "Investor Community" is a Registered Trademark of L.G. Zangani LLC |